A Phase 1 Study of EO-3021 in People With Advanced Esophagogastric Cancers


Full Title

A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients with Solid Tumors Likely to Express CLDN18.2


The purpose of this study is to find the best dose of EO-3021 to treat advanced esophageal, gastroesophageal junction, or stomach cancers. The people in this study have cancers that have spread and stopped responding to treatment. These digestive cancers often have high levels of a protein called CLDN18.2, which can cause cancer cells to grow.

EO-3021 is called an antibody-drug conjugate (ADC). ADCs have two parts: the antibody targets cancer cells. The other part (a chemotherapy drug attached to the antibody) kills cancer cells. EO-3021 binds to  CLDN18.2 and releases the chemotherapy to destroy cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have inoperable or metastatic cancer of the esophagus, stomach, or the junction between the stomach and esophagus.
  • Have cancer that stopped responding to treatment.
  • Have completed prior therapy at least 4 weeks before getting EO-3021.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Steven Maron’s office at 646-888-6780.




Phase I (phase 1)



ClinicalTrials.gov ID